Published February 25, 2025
| Version v1
Journal article
Open
Prevention of tuberculosis in cynomolgus macaques by an attenuated Mycobacterium tuberculosis vaccine candidate
Creators
-
Singh, Dhiraj K.1
- Ahmed, Mushtaq2
- Akter, Sadia2
- Shivanna, Vinay1
- Bucşan, Allison N.3
-
Mishra, Abhishek4
-
Golden, Nadia A.3
- Didier, Peter J.3
-
Doyle, Lara A.3
- Hall-Ursone, Shannan1
-
Roy, Chad J.3
-
Arora, Garima1
-
Dick, Edward J., Jr.1
-
Jagannath, Chinnaswamy1
- Mehra, Smriti1
-
Khader, Shabaana A.2
-
Kaushal, Deepak1
- 1. Texas Biomedical Research Institute
- 2. University of Chicago
- 3. Tulane University
- 4. Houston Methodist Research Institute
Description
The need for novel vaccination strategies to control tuberculosis (TB) is underscored by the limited and variable efficacy of the currently licensed vaccine, Bacille Calmette-Guerin (BCG). SigH is critical for Mycobacterium tuberculosis (Mtb) to mitigate oxidative stress, and in its absence Mtb is unable to scavenge host oxidative/nitrosative bursts. The MtbΔsigH (ΔsigH) isogenic mutant induces signatures of the innate immunity in macrophages and protects rhesus macaques from a lethal Mtb challenge. To understand the immune mechanisms of protection via mucosal vaccination with ΔsigH, we employed the resistant cynomolgus macaque model; and our results show that ΔsigH vaccination significantly protects against lethal Mtb challenge in this species. ΔsigH-vaccinated macaques are devoid of granulomas and instead generate inducible bronchus associated lymphoid structures, and robust antigen-specific CD4+ and CD8+ T cell responses, driven by a hyper-immune, trained immunity-like phenotype in host macrophages with enhanced antigen presentation. Correlates of protection in ΔsigH-vaccinated macaques include gene signatures of T cell activation, IFNG production, including IFN-responsive, activated T cells, concomitant with IFNG production, and suppression of IDO+ Type I IFN-responsive macrophage recruitment. Thus, ΔsigH is a promising lead candidate for further development as an antitubercular vaccine.
Data availability
Source data are provided with this paper. All data supporting the findings of this study are available within this manuscript and its Supplementary Information. Any additional data can be requested from the corresponding authors upon reasonable request. The scRNAseq raw data generated in this study have been deposited to the Gene Expression Omnibus- GEO (NCBI) under accession number GSE283562. The RNAseq dataset have been deposited in the NCBI BioProject database under accession number PRJNA1202673. Source data are provided with this paper.Files
Prevention-of-tuberculosis-in-cynomolgus-macaques.pdf
Additional details
Identifiers
- DOI
- 10.1038/s41467-025-57090-4
- Other
- oai:uchicago.tind.io:14652
Funding
- National Institutes of Health
- AI185028
- National Institutes of Health
- AI134240
- National Institutes of Health
- AI138587
- National Institutes of Health
- AI111914
- National Institutes of Health
- OD011133
- National Institutes of Health
- OD010442
- National Institutes of Health
- OD032443
- National Institutes of Health
- OD028732
- National Institutes of Health
- AI161943
- National Institutes of Health
- AI168439
- National Institutes of Health
- OD028653